Transcript Highlights:

• They're going to enter into a contract, usually with a monthly fee for the services of that physician
• utilization review organizations from using prior authorization that restricts or delays access to FDA-approved
• It restricts or delays access to FDA-approved medications for the treatment of serious mental illness
• This amendment ensures that when a clinician prescribes an FDA-approved medication to treat SMI, an insurer

Summary: The Senate first considered several amendments to a primary care/health care bill. Amendment 1, on artificial intelligence in health care and mental health services, was withdrawn by unanimous consent. Amendment 37, which would have required a rate band for outpatient primary care reimbursement, was debated and then defeated on a roll call, 5-33. Amendment 39, on direct primary care arrangements and deductible credits, was also defeated 5-33. The chamber then took up and passed the conference report for An Act Relative to Teachers Preparation and Student Literacy (H. 5511), with senators emphasizing the need for evidence-based literacy instruction, universal screening, dyslexia screening, teacher training, and implementation funding; the bill was enacted and sent to the Governor after a 39-0 roll call. The Senate then returned to Amendment 60 on the primary care bill, which would have created a “safety valve” allowing alternative payment systems to be proposed to the Health Policy Commission. After debate over whether the bill already allowed flexibility, the amendment was defeated 5-33. Amendment 50, requiring stronger health equity reporting, was adopted. Amendment 66, a technical fix setting commercial payment rates for community health centers at the MassHealth PPS rate, was adopted. Amendment 24, excluding pharmaceutical spending from the primary care spending baseline and target, was adopted. Amendment 45, a study on expanding the role of allied health professionals, was withdrawn. Amendment 48, a group purchasing cooperative pilot, and amendments 53, 61, and 63 were also withdrawn. The Senate adopted Amendment 64, which prohibits prior authorization from delaying FDA-approved medications for serious mental illness, and rejected Amendment 68 on reporting private equity investment in primary and specialty care, as well as Amendments 71 and 72 on scope of practice and ownership disclosure. Amendment 62, a technical change modernizing the definition of primary care and clarifying the care team, was adopted. Amendment 21, the Senate Ways and Means amendment, was then adopted, the bill was ordered to a third reading, and the Senate passed An Act relative to primary care for you (S. 3116) to be engrossed on a 35-4 roll call. The Senate then adjourned to a later date, with memorial references at adjournment.

Transcript Highlights:

• You know, and I don't know That we or the FDA or anybody knows what a toxic level, a blood serum level
• It's 5.1 grams a day was on average what a small group of kratom users use average on a day.”

Summary: The working group met for a legislative-only discussion on kratom ahead of a special session, with members agreeing to keep remarks brief and noting a public open house and expert testimony would follow the next week. Staff provided an overview of kratom regulation, describing the substance, its psychoactive effects, reported health risks, federal DEA action on 7-OH, state approaches, and North Dakota’s recent executive action and special session call. Legislators then debated whether the state should prohibit kratom, regulate it, or distinguish between natural kratom and synthetic or concentrated 7-OH products. Several members cited extensive testimony from the 2025 session, including House Bill 1101, which would have scheduled kratom as a Schedule I substance and failed in the House, and House Bill 1566, which evolved into a study. Supporters of regulation emphasized testimony from people who said natural kratom helped with chronic pain or function, while others stressed concerns about addiction, adulterated products, youth access, infant withdrawal, and deaths linked to kratom or 7-OH. Members also discussed enforcement and public health issues, including whether the Good Samaritan law should be updated, how law enforcement would respond under the executive order, and whether withdrawal could drive people toward harder drugs. One member urged a temporary approach until the 2027 session, while others argued the short special session could still address a narrow ban on 7-OH and tighter controls on natural kratom. No votes were taken, and the meeting ended with plans for additional testimony and further legislative hearings during the special session.

Transcript Highlights:

• When you combine these losses at the state level with those at CDC and FDA, we are no longer able to
• with those at losses at the state level with those at CDC<00:07:47.280><c> and</c><00:07:47.599><c> FDA
• , we are no longer able to CDC and FDA, we are no longer able to investigate<00:07:50.639><c> the</c>
• you because<00:21:12.799><c> it</c><00:21:13.039><c> is</c><00:21:13.120><c> a</c><00:21:13.280><c> fee
• for service program because it is a fee for service program and<00:21:14.640><c> so</c><00:21:14.799

Summary: Sen. Erin Maye Quade, Rep. Esther Abad, and other Minnesota DFL legislators held a press event focused on responding to Trump administration and federal Republican actions that they said threaten health care, education, housing, public health, and other state services. Speakers argued Minnesota must not make “false trade-offs” between core services and should instead protect programs like Medicaid, school funding, disability services, nutrition, and public health by raising additional revenue and closing tax breaks for wealthy individuals and corporations. Rep. Abad and others outlined possible revenue options, including a fifth-tier income tax, a corporate rate match, closing tax exemptions for luxury items and second homes, a social media tax, and ending data center tax exemptions. They said these measures would not fully replace possible federal cuts, but could help mitigate harm and preserve services. Several speakers also criticized Republican opposition to tax increases and said the state should ask wealthy taxpayers and corporations to contribute more. Testimony from Olivia Dylan, a laid-off Minnesota Department of Health epidemiologist, described the impact of federal public health funding cuts and MDH layoffs on outbreak response, nursing home support, lab work, and tribal public health. Sean Leaden of SEIU Local 284 described low pay and staffing shortages among hourly school workers and said underfunding has hurt students and employees. Sen. Doran Clark and Rep. Emma Greenman framed the issue as both a budget and democracy question, arguing that federal cuts and attacks on public programs undermine self-governance and community well-being. In response to questions, speakers said Minnesota cannot fully backfill expected federal Medicaid losses, but can use state tools to reduce harm and should press Republicans to identify what services they would cut instead.

Transcript Highlights:

• , and some of these have even received breakthrough therapy designation by the FDA.
• They're sponsored by drug developers who are seeking FDA approval.
• FDA to treat 24.
• approval. ...and reduce suffering now, not wait 20 years for FDA approval.
• Support among lots of key people at HHS, VA, and FDA.

Summary: The Senate Ad Hoc Committee on Access to Breakthrough Mental Health Therapies met to discuss psychedelic-assisted treatments for serious mental health conditions, with a focus on psilocybin, ibogaine, MDMA, and related compounds. The chair framed the issue as a clinical and access problem for veterans, first responders, and others with PTSD, depression, TBI, addiction, and suicidal ideation, emphasizing that these therapies are intended for supervised medical settings rather than take-home use. Members reviewed research claims and policy trends, including FDA breakthrough therapy designations, state-level psychedelic legislation, and the role of Arizona’s right-to-try law in expanding access once federal approval is in place. Testimony came from Alan Mullen, a retired Army Special Forces veteran, who described his PTSD/TBI history and said ibogaine treatment helped him confront trauma and showed promise in reducing symptoms under strict medical monitoring. Dr. Sue Cisley of Scottsdale Research Institute described ongoing FDA-controlled trials in Arizona, said current medications often fail high-need patients, and urged removal of research barriers and preparation for right-to-try and expanded access. Dan Freiberg of the Professional Firefighters of Arizona said firefighters face chronic exposure to trauma, often rely on alcohol or other coping mechanisms, and need effective alternatives beyond traditional therapy. Dr. Chung Trin discussed late-stage psychedelic trials, the FDA breakthrough pathway, safety oversight, and the need for state readiness when approvals occur. Committee members asked about how the treatments work, whether they require psychotherapy support, safety concerns including suicidality and black-market abuse, patenting and synthetic versus natural versions, and costs compared with ketamine and other treatments. Witnesses said the therapies are administered with extensive screening, monitoring, and integration support, and argued that addiction potential appears low under medical supervision. The discussion ended with interest in sending correspondence to federal officials to support right-to-try cooperation and in continuing the research and policy work; no formal vote or action was taken in the portion provided.

Transcript Highlights:

• , and some of these have even received breakthrough therapy designation by the FDA.
• , and some of these have even received breakthrough therapy designation by the FDA.
• They're sponsored by drug developers who are seeking FDA approval.
• And we only have FDA approval to treat 24.
• So Support among lots of key people at HHS, VA, and FDA.

Summary: The Senate Ad Hoc Committee on Access to Breakthrough Mental Health Therapies held an informational hearing focused on psychedelic-assisted treatments for PTSD, depression, addiction, and related conditions, especially for veterans, first responders, and firefighters. The chair framed the issue as a response to long-standing barriers created by Schedule I restrictions and stigma, emphasizing that the committee was looking at supervised clinical use rather than take-home drugs. Members discussed the growing number of state psychedelic policy proposals, the federal breakthrough therapy pathway, and the idea of Arizona preparing for FDA approval and possibly sending correspondence to federal officials in support of expanded access and Right to Try implementation. Witnesses included retired Army Special Forces Master Sgt. Alan Mullen, who described participating in an ibogaine study for PTSD/TBI and said the treatment, combined with preparation and integration support, helped him confront trauma and showed promise under strict medical monitoring. Dr. Sue Sisley of Scottsdale Research Institute testified that her team is conducting FDA-controlled psychedelic trials, including psilocybin research funded by Arizona, and argued that these therapies can produce major symptom relief with limited doses when delivered in controlled settings. She also urged the legislature to help remove barriers to research and access, including support for Right to Try and possible federal action to allow controlled-substance access. Dan Freiberg of the Professional Fire Fighters of Arizona said firefighters face chronic mental health exposure and often lack effective options beyond traditional therapy or, in some cases, ketamine, and he supported any safe, effective treatment that could help members return to work and reduce suicide risk. Dr. Chung Trin, a mental health physician and trial investigator, explained the FDA breakthrough designation process, said several psychedelic treatments are in late-stage review, and stressed the need for Arizona to build clinical infrastructure so patients can access approved therapies quickly and safely once federal approval occurs. Committee members asked about safety, addiction potential, suicide risk, costs, patents, and whether natural versus synthetic versions of compounds like psilocybin would be available; the hearing ended with general support for continued research, possible legislative correspondence to federal officials, and no formal vote or bill action taken.

Transcript Highlights:

• Atkins, do you agree that private fund managers are charging higher fees?
• Well, Senator, there's a whole range of fees that are done, but I would, to your point there as far as
• So you're saying that investors should be protected by making sure that they know what those fees are
• So the typical management fee for a private fund can be four times higher than the annual fee for a mutual
• Just be able to ask, you know, when it comes to the FDA.

Committee: Senate Banking, Housing, and Urban Affairs Committee

Keywords: financial regulations, SEC, Comptroller of the Currency, Federal Transit Administration, nominees, Empowering Main Street in America Act, capital formation, economic growth

Summary: The committee meeting focused on several nominees within key financial institutions, including discussions surrounding the SEC, the Federal Transit Administration, and the Comptroller of the Currency. Notable dialogue included concerns over regulatory balance, with various members emphasizing a need to streamline regulations to foster innovation while ensuring accountability and safety for investors. The importance of the proposed 'Empowering Main Street in America Act' was highlighted as a means to facilitate access to capital for small businesses, underlining the current administration's approach towards financial regulations.

Transcript Highlights:

• Credit card fees used to be about 50% of our sales.
• They set the fees. They set the interchange.
• Every swipe has a significant fee to it.
• If an operator pays meals tax with a credit card, a 2.09% fee is added for a debit card or a 2.39% fee
• Is it about collecting licensing fees?

Committee: Joint Joint Committee on Consumer Protection and Professional Licensure

Summary: The committee opened a hearing of the Joint Committee on Consumer Protection and Professional Licensure and reviewed a broad agenda including credit card fees, event ticketing, music therapy licensure, senior psychologist licensure, CPA pathways, school mental health licensure, and a bill regulating alternative healing therapies. The chairs explained hearing logistics, including three-minute testimony limits and submission of written testimony, and noted that more than 70 people had signed up to testify. Legislators and advocates were heard out of order throughout the day. A major portion of the hearing focused on credit card surcharge and interchange legislation. Restaurant owners, the Massachusetts Restaurant Association, NFIB, and other small-business witnesses supported bills allowing merchants to add convenience fees and, in one proposal, preventing card companies from charging fees on tax and tip portions of transactions. They argued that swipe fees are a major and growing cost, especially for restaurants, and that Massachusetts is one of only two states that bars surcharges. Opponents from the Cooperative Credit Union Association, the Electronic Payment Coalition, and the Electronic Transactions Association warned that the proposals would create compliance burdens, fragment the payment system, raise legal preemption issues, and disrupt a system they described as efficient and secure. The committee also heard competing testimony on ticket transferability and ticket resale. Supporters, including the National Consumers League and Sports Fans Coalition, said bills on ticket transferability would protect consumers who cannot attend events and would increase competition and savings in the secondary market. Opponents, including United Musicians and Allied Workers and theater owners, argued that mandatory transferability would weaken artists’ and venues’ ability to prevent scalping and predatory resale, and that some ticket sellers should be exempt from the broader ticketing regulations. Separate testimony supported music therapy licensure, senior psychologist licensure, and new CPA education pathways, with witnesses saying these measures would expand access to care and strengthen the workforce while maintaining professional standards. The hearing also drew extensive opposition to S.261 on alternative healing therapies, with practitioners and clients arguing it would overregulate spiritual and holistic practices and was not an effective response to human trafficking concerns.

Transcript Highlights:

• fees.
• fees.
• for a decrease in fees to increase grace periods.
• The Louisiana Tax Commission has some self-generated fees.
• We're looking to extend that fee until 2030.

Bills: HR58 , HR59 , HR60 , HR61 , HR62 , HR63 , HR64 , HCR32 , HB43 , HB447 , HB573 , HB1000 , HB1001 , HB1002 , HB1003 , HB1004 , HB1005 , HR46 , HR48 , HR50 , HR51 , HR52 , HR53 , HR54 , HR55 , HR56 , HR57 , HCR31 , HB20 , HB21 , HB166 , HB494 , HB710 , HB795 , HB985 , HB986 , HB987 , HB988 , HB989 , HB990 , HB991 , HB992 , HB993 , HB994 , HB995 , HB996 , HB997 , HB998 , SB128 , SB149 , SB174 , SB191 , SB205 , SB213 , SB218 , SB220 , SB229 , SB238 , SB243 , SB375 , SB379 , HB8 , HB9 , HB10 , HB15 , HB16 , HB17 , HB18 , HB19 , HB22 , HB33 , HB34 , HB35 , HB44 , HB46 , HB47 , HB48 , HB61 , HB101 , HB126 , HB135 , HB142 , HB164 , HB185 , HB215 , HB226 , HB232 , HB233 , HB242 , HB284 , HB292 , HB297 , HB301 , HB334 , HB436 , HB468 , HB548 , HB571 , HB582 , HB593 , HB594 , HB609 , HB613 , HB712 , HB722 , HB732 , HB746 , HB781 , HB827 , HB845 , HB848 , HB921 , HB923 , HB951 , HB953 , HB999 , HB129 , HB130 , HB287 , HB489 , HB545 , HB553 , HB555 , HB570 , HB854 , HB952 , HB28 , HB36 , HB50 , HB52 , HB56 , HB62 , HB68 , HB92 , HB110 , HB117 , HB119 , HB124 , HB140 , HB147 , HB171 , HB182 , HB193 , HB196 , HB203 , HB228 , HB234 , HB260 , HB268 , HB271 , HB285 , HB289 , HB351 , HB400 , HB413 , HB469 , HB534 , HB551 , HB552 , HB574 , HB576 , HB634 , HB649 , HB677 , HB735 , HB739 , HB779 , HB784 , HB796 , HB842 , HB850 , HB919 , HB149 , HB733 , HB875 , HB868 , HB901

Keywords: waterfowl conservation, wetlands preservation, Ducks Unlimited, environmental stewardship, Louisiana, tennis, athlete recognition, family legacy, sports achievements, coaching, student parents, higher education, academic support, family stability, workforce equity, Homeland Security, federal funding, public safety, emergency services, TSA

Transcript Highlights:

• And the large energy user must enter into a long-term contract with the utility, including exit fees,
• Senator Pettyjohn: Back to the fines and fees and restitution.
• Fines and fees that are currently assessed against defendants.
• So the fines and fees are not part of the bill, which I said before.
• So it, rights on payment fines and fees and restitutions.

Summary: The Senate received communications from the House on numerous measures, including several bills and resolutions passed with amendments, committee reports on bills such as large energy use facilities, campaign finance, voting rights, and appropriations, and a list of pre-file legislation. The chamber then moved through a long floor session with confirmations, bill readings, and roll-call votes, ultimately confirming the nomination of Morgan T. Zern to the Delaware Supreme Court by a 21-0 vote. Among the major policy items considered were property tax and school tax measures tied to the statewide reassessment. The Senate passed House Bill 460, clarifying monthly municipal permit-data reporting to New Castle County; House Bill 461, granting temporary authority for New Castle County school districts to reset school tax rates for one cycle; and House Bill 462, making the split school tax rate permanent with a lower nonresidential cap. Members discussed the fiscal effects at length, including testimony from a school district finance officer that HB 461 would allow revenue-neutral rate setting and offset the fiscal note on HB 462. The Senate also passed House Bill 365 creating a Delaware Indigenous Affairs Commission, House Bill 458 on backflow requirements for low-hazard buildings, Senate Bill 27 establishing the Office of New Americans with a sunset and interagency coordination, and Senate Bill 315 on the Delaware Technical Innovation Program. The chamber also approved Senate Substitute 1 for Senate Bill 300, a firearms dealer regulation bill, after extensive debate over amendments, confidentiality, background checks, and the balance between public safety and burdens on lawful dealers. Several members raised constitutional and practical objections, while supporters argued the bill would reduce trafficking, straw purchases, and theft from dealers. In addition, the Senate passed House Bill 305 creating a diabetes wellness pilot program, with supporters emphasizing the state’s diabetes burden and the program’s federal funding, and House Concurrent Resolution 157, which asks the State Lottery Office to report on iLottery’s impact on small businesses. Senate Bill 325, a fire prevention/background-check bill, was laid on the table after concerns about a late House amendment and requests for more time to consult stakeholders.

Transcript Highlights:

• The FDA requires a limited amount of time for opioids and a renewal process that is much shorter than
• And so what this bill does is basically say that the users in New Mexico shall not share Basically say
• that the users in New Mexico shall not share or sell the information if there is a reasonable belief
• But that fund—those fees are already being collected and used for a number of things.
• public school, we pay to and from transportation, but we're simply talking about pretty much a set fee

Transcript Highlights:

• We, because of state law, cannot have our members receive lower-cost, equally effective, FDA-approved
• Thank you. ...even when the biosimilar is FDA-approved and clinically equivalent for that patient.
• This is what the FDA is finding out and they’re changing their policies.
• And I think I heard you say that’s a designation from Congress or FDA. Congress. From Congress.
• So FDA doesn’t recognize the difference between a biosimilar and an interchangeable biosimilar.

Committee: Senate Business, Professions and Economic Development

Transcript Highlights:

• We, because of state law, cannot have our members receive lower-cost, equally effective, FDA-approved
• Thank you. ...even when the biosimilar is FDA-approved and clinically equivalent for that patient.
• This is what the FDA is finding out and they’re changing their policies.
• And I think I heard you say that’s a designation from Congress or FDA.” “Congress. From Congress.
• So FDA doesn’t recognize the difference between a biosimilar or an interchangeable biosimilar.

Summary: The Senate Business, Professions and Economic Development Committee heard SB 1094 by Senator Weber Pearson, which would expand pharmacist and health plan authority to substitute biosimilars for reference biologic drugs in order to lower prescription drug costs. The author and supporters, including Blue Shield of California, Sharp HealthCare, and several business and health groups, argued that biologics are a major driver of rising health care spending and that biosimilars can provide substantial savings while maintaining safety and efficacy. The bill also included transparency provisions and committee amendments, including notice requirements and clarifications around substitution and exceptions. Opposition came from the Biotechnology Innovation Organization, the California Rheumatology Alliance, and Biocom, who said the bill was not scientifically justified, could undermine FDA standards, and might lead to unwanted switching, side effects, or delays in care for patients with chronic conditions. They emphasized that pharmacists can already substitute interchangeable biosimilars and that non-interchangeable products can be changed with prescriber contact. Committee discussion focused on patient safety, the meaning of “do not substitute,” the 30-day notice provisions, and the distinction between biosimilars and interchangeable biosimilars. After debate, the committee adopted a due pass as amended motion to the Senate Health Committee. The bill passed the committee on a 10-0 roll call vote and was sent onward.

Transcript Highlights:

• One of the potential ways out is the AHEAD program, because a fee-for-service billing is going to screw
• The way to do that is to get out of fee-for-service and to a value-based program.
• in how devices are not just created safely but also marketed wisely and so the gap between when the FDA
• FDA to approve the device that would save lives, it turns out, with clinical trials proving this. money
• your point, we should make it easier for industry. to create life-saving tools by aligning when the FDA

Committee: Senate Finance Committee

Keywords: Michael Falkender, Deputy Secretary of the Treasury, IRS, taxpayer privacy, nomination process, committee hearing

Summary: The committee convened to discuss critical issues surrounding the nomination of Michael Falkender for the position of Deputy Secretary of the Treasury. This meeting included a series of remarks from committee members who expressed divergent views on Falkender's qualifications and the implications of his appointment. Senator Wyden voiced strong opposition, arguing that Falkender represents harmful policies expected to be perpetuated under the current administration, especially concerning taxpayer privacy and IRS tactics. Meanwhile, other members defended Falkender, noting his extensive experience, including a commitment to transparency in government operations if confirmed.

Transcript Highlights:

• Engagement-based algorithms populate users' feeds with whatever is most likely to maximize likes, shares
• The only goal is to keep users' eyes watching social media for as long as possible so the companies can
• The challenge was delivered to young users' feeds by engagement-based algorithms.
• I'm also an active social media user, and while I value the connections it creates, I'm often struck
• as regulations are implemented to share insights from the field, help align with federal positions, FDA

Committee: Joint Joint Committee on Advanced Information Technology, the Internet and Cybersecurity

Summary: The committee held a hearing on several artificial intelligence bills, opening with remarks about the 9/11 anniversary and then broad statements from the co-chairs about AI’s promise and risks. Chair Farley-Bouvier and Senator Moore emphasized the need for guardrails, transparency, and worker and consumer protections, while Senator Finegold described Senate Bill 37, which would create a framework for AI model training with safety assessments, audits, incident reporting, Attorney General oversight, and workforce reporting. Members also discussed Massachusetts’ position relative to other states and the need for state action in the absence of federal regulation. A large portion of the hearing focused on the Fair Act, House 77 and Senate 35, which would limit workplace surveillance, restrict collection of biometric and location data, require notice and human review for automated employment decisions, and protect workers from retaliation. Labor leaders, including AFL-CIO, AFSCME, AFT, SEIU, building trades, and other worker representatives, testified in support, describing harms from bossware, automated benefits denials, hiring and promotion screening, scheduling, and monitoring in workplaces ranging from health care and education to manufacturing and construction. They argued that AI systems are already affecting wages, benefits, safety, and job security, and that Massachusetts should act now to set clear rules. The committee also heard testimony on House Bill 74, which would require informed consent and clear contract terms for digital replicas of voices and likenesses, with SAG-AFTRA representatives supporting the bill as a protection for performers and creators. Another major topic was Senate Bill 51 on social media algorithm accountability and transparency; child safety advocates, researchers, and a public health expert described harms from engagement-based algorithms, including exposure to harmful content, eating disorders, and youth mental health impacts, and supported independent audits and public reporting. A few industry and civil liberties witnesses supported regulation but urged balance, warning against overly burdensome rules while acknowledging the need for privacy, transparency, and accountability. No votes or final committee actions were taken in the hearing excerpt.

Transcript Highlights:

• This bill moves towards solving an issue, making sure our streaming services do not pay franchise fees
• , and adds language to ensure that anyone who currently pays franchise fees continues to pay these fees
• of last things, the House included language if the United States Food and Drug Administration, the FDA
• The goal of which is if we can get enough states moving on this, I think that we can reform our FDA and

Bills: HB4 , HB20 , HB40 , HB46 , HB 101 , HB 112 , HB 117 , HB 121 , HB 127 , HB146 , HB150 , HB186 , HB229 , HB426 , HB521 , HB541 , HB549 , HB632 , HB713 , HB796 , HB 1052 , HB 1106 , HB 1135 , HB 1234 , HB 1306 , HB1403 , HB1523 , HB1532 , HB1690 , HB1960 , HB2035 , HB2217 , HB2399 , HB2488 , HB2517 , HB2594 , HB2655 , HB2686 , HB2731 , HB2757 , HB2820 , HB2963 , HB3005 , HB3053 , HB3073 , HB3225 , HB3320 , HB3333 , HB3336 , HB3441 , HB3483 , HB3516 , HB3520 , HB3697 , HB3748 , HB3793 , HB3848 , HB4099 , HB4134 , HB4144 , HB4158 , HB4233 , HB4236 , HB4285 , HB4350 , HB4359 , HB4464 , HB4580 , HB4690 , HB4730 , HB4848 , HB4904 , HB4995 , HB5196 , HB5294 , HB5381 , HB5435 , HB5437 , HB5509 , HB5606 , HB5646 , HB5658 , HB5661 , HB5663 , HB5666 , HB5672 , HCR40 , HCR59 , SB867 , SB2919 , SJR5 , SJR27 , SB4 , SB6 , SB7 , SB9 , SB13 , SB15 , SB23 , SB27 , SB30 , SB40 , SB57 , SB66 , SB140 , SB268 , SB293 , SB331 , SB413 , SB447 , SB457 , SB467 , SB506 , SB510 , SB512 , SB571 , SB650 , SB763 , SB777 , SB785 , SB800 , SB850 , SB863 , SB865 , SB973 , SB974 , SB1191 , SB1281 , SB1300 , SB1362 , SB1494 , SB1522 , SB1540 , SB1567 , SB1579 , SB1580 , SB1610 , SB1660 , SB1723 , SB1760 , SB1838 , SB1923 , SB1946 , SB1957 , SB1964 , SB2018 , SB2024 , SB2121 , SB2167 , SB2217 , SB2221 , SB2321 , SB2337 , SB2368 , SB2373 , SB2407 , SB2431 , SB2477 , SB2587 , SB2615 , SB2753 , SB2807 , SB2900 , SB2965 , SB2972 , SB2986 , SB3039 , SB3047 , SB3059 , SB3070 , SB1 , SB17 , SB21 , SB260 , SB379 , SB509 , SB1198 , SB1405 , SB1506 , SB1637 , SB1833 , SB2155 , SB2308 , SB2601 , SB2778 , HB300 , HB2011 , HB2525 , HB5246 , HB 100 , HB 101 , HB 119 , HB227 , HB252 , HB322 , HB346 , HB654 , HB705 , HB718 , HB721 , HB824 , HB 1094 , HB 1234 , HB 1306 , HB1506 , HB1523 , HB1629 , HB1690 , HB1868 , HB1960 , HB1973 , HB2012 , HB2035 , HB2037 , HB2078 , HB2128 , HB2213 , HB2240 , HB2348 , HB2520 , HB2598 , HB2686 , HB2694 , HB2820 , HB3005 , HB3057 , HB3092 , HB3112 , HB3171 , HB3181 , HB3185 , HB3333 , HB3388 , HB3516 , HB3546 , HB3619 , HB3623 , HB3629 , HB3642 , HB3686 , HB3697 , HB3749 , HB3793 , HB3812 , HB3815 , HB3848 , HB3909 , HB4081 , HB4145 , HB4157 , HB4158 , HB4170 , HB4202 , HB4211 , HB4214 , HB4233 , HB4285 , HB4350 , HB4361 , HB4463 , HB4464 , HB4466 , HB4559 , HB4630 , HB4748 , HB4765 , HB4848 , HB4894 , HB4904 , HB4995 , HB5093 , HB5196 , HB5320 , HB5437 , HB5624 , HB5650 , HB5651 , HB5652 , HB5654 , HB5655 , HB5656 , HB5658 , HB5661 , HB5662 , HB5664 , HB5665 , HB5666 , HB5670 , HB5672 , HB5674 , HB5677 , HB5679 , HB5682 , HB5689 , HB5690 , HB5694 , HB5695 , HB5698 , HB5699 , HCR46 , HCR76 , HCR81 , HCR83 , HCR84 , HCR111 , HB748 , HB5652 , HB3395 , HB180 , HB 1306 , HB5650 , HB4894 , HB1629 , HB5698 , HB3171 , HB2694 , HB5664 , HB4690 , HB4464 , HB3623 , HB2520 , HB2213 , HB252 , HB146 , HB5596 , HB3619 , HB5320 , HB5651 , HB5670 , HB5665 , HB5437 , HB5679 , HB5661 , HB5662 , HB5654 , HB5672 , HB5656 , HB2035 , HB721 , HB346 , HB5695 , HB5694 , HB5674 , HB3185 , HB2348 , HB 1135 , HB 101 , HB5666 , HB5677 , HB5682 , HB5658 , HB4144 , HB3642 , HB3815 , HB2686 , HB2012 , HB1960 , HB227 , HB654 , HB4158 , HB4630 , HB1523 , HB1973 , HB3333 , HB3697 , HB3546 , HB3225 , HB2820 , HB186 , HB 119 , HB4466 , HB4170 , HB3909 , HB4081 , HB4145 , HB4285 , HB4463 , HB4995 , HB5624 , HB1449 , HB2598 , HB3629 , HB4361 , HB824 , HB1868 , HB4848 , HB40 , HB 117 , HB3686 , HB3793 , HB 112 , HB 104 , HB718 , HB4904 , HB4202 , HB4765 , HB4559 , HB4350 , HB4214 , HB3388 , HB3112 , HB5196 , HB3516 , HB3092 , HB4233 , HB 1094 , HB2037 , HB3005 , HB3848 , HB 121 , HB3336 , HB5294 , HB5646 , HB4236 , HB 1052 , HB5509 , HB5435 , HB3520 , HB3320 , HB2517 , HB2488 , HB5663 , HB2731 , HB3073 , HB2655 , HB2399 , HB541 , HB4099 , HB 111 , HB1532 , HB3483 , HB2963 , HB4580 , HB3748 , HB713 , HB632 , HB426 , HB4730 , HB 127 , HB5690 , HB5689 , HB5655 , HB3385 , HB2757 , HB4359 , HB5381 , HB20 , HB 123 , HB549 , HB5606 , HB2217 , HB2594 , HB796 , HB 1057 , HB3664 , HCR141 , HCR40 , HCR59 , HCR76 , HCR81 , HCR46 , HCR111 , HCR83 , HCR84 , SJR36 , SJR50 , SJR63 , SCR12 , SCR39 , SB2023 , SB62 , SB666 , SB847 , SB284 , SB854 , SB810 , SB1505 , SB583 , SB507 , SB1434 , SB1772 , SB2016 , SB1122 , SB731 , SB397 , SB508 , SB1436 , SB287 , SB1882 , SB393 , SB1791 , SB209 , SB2429 , SB1085 , SB1975 , SB2717 , SB1262 , SB636 , SB2056 , SB884 , SB1200 , SB1845 , SB2458 , SB801 , SB3014 , SB3013 , SB758 , SB2797 , SB2076 , SB2876 , SB1640 , SB1449 , SB1181 , SB1234 , SB2926 , SB2841 , SB1528 , SB1854 , SB317 , SB1250 , SB2082 , SB1237 , SB2819 , SB629 , SB2608 , SB1602 , SB2009 , SB867 , SB640 , SB1698 , SB2680 , SB913 , SB1071 , SB1086 , SB1087 , SB1483 , SB1444 , SB1553 , SB1556 , SB1703 , SB2133 , SB2297 , SB2298 , SB2622 , SB2955 , SB2334 , SB1367 , SB2044 , SB2363 , SB2565 , SB1888 , SB3036 , SB3057 , SB3043 , SB3063 , SB3035 , SB203 , SB2688 , SB2522 , SB2459 , SB2655 , SB2251 , SB1884 , SB2928 , SB2566 , SB2549 , SB2553 , SB2919 , SB1944 , SB1232 , SB1798 , SB2603 , SB2607 , SB2683 , SB1319 , SB3045 , SB3071 , HB40 , HB 117 , HB 121 , HB426 , HB541 , HB713 , HB 1052 , HB1532 , HB2217 , HB2488 , HB2517 , HB2655 , HB2757 , HB2963 , HB3073 , HB3697 , HB4099 , HB4144 , HB4158 , HB4236 , HB4285 , HB4848 , HB5435 , HB5437 , HB5509 , HB5646 , HB5666 , HB14 , HB 1240 , HB796 , HB1523 , HB5294 , SR559 , SR587 , SR614 , SCR53 , SJR59 , SB10 , SB22 , SB25 , SB34 , SB36 , SB38 , SB261 , SB777 , SB924 , SB1188 , SB1318 , SB1333 , SB1398 , SB1448 , SB1621 , SB1862 , SB2405 , SB2406 , SB8 , SB12 , SB37 , SB441 , SB1566 , SB2878 , HB300 , HB2011 , HB5246 , HB 101 , HB 119 , HB227 , HB252 , HB346 , HB654 , HB718 , HB721 , HB824 , HB 1306 , HB1629 , HB1868 , HB1960 , HB1973 , HB2012 , HB2035 , HB2037 , HB2213 , HB2348 , HB2520 , HB2598 , HB2686 , HB2694 , HB2820 , HB3005 , HB3092 , HB3112 , HB3185 , HB3333 , HB3388 , HB3516 , HB3546 , HB3619 , HB3623 , HB3629 , HB3642 , HB3686 , HB3815 , HB3848 , HB3909 , HB4081 , HB4145 , HB4170 , HB4202 , HB4214 , HB4350 , HB4361 , HB4463 , HB4464 , HB4466 , HB4559 , HB4630 , HB4765 , HB4894 , HB4904 , HB4995 , HB5196 , HB5320 , HB5624 , HB5650 , HB5651 , HB5652 , HB5654 , HB5655 , HB5656 , HB5658 , HB5661 , HB5662 , HB5664 , HB5665 , HB5670 , HB5672 , HB5674 , HB5677 , HB5679 , HB5682 , HB5695 , HB5698 , HCR46 , HCR76 , HCR81 , HCR83 , HCR84 , HCR111 , HB 1094 , HB3171 , HB3793 , HB4233 , HB5689 , HB5690 , HB5694

Transcript Highlights:

• And it's not FDA approved for pain, but people are still using it.
• And it's not FDA<01:20:25.280><c> approved</c><01:20:25.600><c> for</c><01:20:25.760><c> pain,</c><01
• I would look at the FDA language and match that.
• is already regulated and how the FDA is already regulated and how their<01:25:09.920><c> language.
• I would look at the FDA their language.

Committee: House Health, Human Services and Elderly Affairs

Transcript Highlights:

• We, because of state law, cannot have our members receive lower-cost, equally effective, FDA-approved
• Even when the biosimilar is FDA-approved and clinically equivalent for that patient, this means that
• This is what the FDA is finding out and they’re changing their policies.
• But first of all, there’s the drug itself, which has gone through the FDA for initial approval.
• So FDA doesn’t recognize the difference between a biosimilar or an interchangeable biosimilar.

Committee: Senate Business, Professions and Economic Development

Summary: The Senate Business, Professions and Economic Development Committee heard SB 1094 by Senator Weber Pierson, which would expand pharmacist substitution authority for biosimilars and allow health plans to require use of lower-cost generic or biosimilar alternatives when available, unless the prescriber marks “do not substitute.” The author said the bill is intended to lower prescription drug costs, improve access, and require insurers to report on whether substitutions reduce out-of-pocket costs and premium growth. Committee amendments were accepted, including changes to align definitions with federal law, require a link to the FDA Purple Book, add a 30-day advance notice requirement for plan-driven substitutions, and allow exceptions for patients or providers. Supporters included Blue Shield of California, Sharp HealthCare, health plans, CVS, the California Chamber of Commerce, and other business and health care groups, who argued the bill would increase competition, reduce costs, and remove administrative barriers to using FDA-approved biosimilars. Opponents and “opposed unless amended” witnesses, including the Biotechnology Innovation Organization, the California Rheumatology Alliance, and some physician groups, argued the bill goes beyond current FDA interchangeability standards, could undermine physician judgment, and may create patient safety concerns for some chronic-disease patients who react differently to biosimilars or experience problems with multiple switches. Committee members discussed the “do not substitute” option, patient notification, insurance approval, and whether the bill preserves physician discretion. After debate, Senator Arreguín moved the bill, and the committee voted 10-0 to pass SB 1094 as amended to the Senate Health Committee.

Transcript Highlights:

• include the claims data that's in the APCD they're allowed to pull from peer-reviewed studies from FDA
• Are y'all willing to supply that data as far as your administrative fees or costs?
• Okay, well I'm worried about the administrative fee that y'all are going to charge us to make us pay.
• So the increase of insurance more to take care of an administrative fee you're talking about well I'm
• But if this cost is already included and the fees you're getting now.

Bills: HB138 , HB335 , HB388 , HB138

Committee: House Insurance

Keywords: health impact analysis, cost analysis, coverage mandates, health insurance, legislative analysis, health care data, education, funding, classroom resources, teacher support, student outcomes, health benefits, provider dentists, payment reimbursement, insurance code, noncontracting, dental care, reimbursement, health benefit plans, noncontracting providers

Transcript Highlights:

• And it is my client who bears the risk of failure because my client is going to pay my fees no matter
• And it is my client who bears the risk of failure because my client is going to pay my fees no matter
• </c> ...going to pay my fees no matter what.
• </c> a simple contingency, uh, fee a simple contingency, uh, fee arrangement,<01:47:11.120><c> which<
• I did not uh crypto users to the IRS.

Committee: House Judiciary

Transcript Highlights:

• 952 by Representative Jordan, relative to consumer loans, maximum loan finance charges, origination fees
• , suspension of penalties, credit education program, and license renewal fees.
• It is going to increase some of the fees that they charge to these finance companies.
• A $25 fee? I doubt if that's because that's a company fee. But I get your point on that.

Bills: HR133 , HR134 , HR135 , HR136 , HR137 , HR138 , HR139 , HR140 , HR141 , HR142 , HR143 , HR144 , HR145 , HR146 , HR147 , HR148 , HR149 , HR150 , HR151 , HR152 , HR119 , HR120 , HR121 , HR122 , HR123 , HR125 , HR126 , HR127 , HR128 , HR129 , HR130 , HR131 , HR132 , HCR53 , HCR54 , HCR55 , HCR56 , SCR3 , SCR22 , SB4 , SB18 , SB66 , SB106 , SB201 , SB256 , SB274 , SB292 , SB326 , SB386 , SB406 , SB422 , SB423 , SB456 , SB475 , HCR3 , HB1 , HB3 , HB27 , HB71 , HB214 , HB225 , HB241 , HB244 , HB306 , HB312 , HB313 , HB314 , HB345 , HB366 , HB383 , HB446 , HB473 , HB511 , HB514 , HB655 , HB730 , HB743 , HB836 , HB983 , HB1027 , HB1037 , HB1043 , HB1082 , HB1091 , HB1096 , HB1103 , HB1126 , HB1167 , HB1174 , HB1175 , HB1230 , HB1237 , HB1238 , SB162 , SB349 , SB350 , SB382 , SB383 , HB76 , HB132 , HB181 , HB210 , HB250 , HB265 , HB275 , HB291 , HB322 , HB342 , HB475 , HB486 , HB616 , HB635 , HB639 , HB690 , HB740 , HB757 , HB761 , HB774 , HB808 , HB855 , HB872 , HB883 , HB886 , HB903 , HB949 , HB962 , HB996 , HB1003 , HB1036 , HB1054 , HB1071 , HB1076 , HB1078 , HB1113 , HB1132 , HB1146 , HB1232 , HB1233 , HB21 , HB24 , HB29 , HB31 , HB39 , HB45 , HB77 , HB136 , HB150 , HB263 , HB273 , HB299 , HB315 , HB376 , HB377 , HB431 , HB444 , HB450 , HB519 , HB533 , HB538 , HB559 , HB562 , HB663 , HB664 , HB715 , HB717 , HB805 , HB822 , HB823 , HB834 , HB864 , HB867 , HB1017 , HB1018 , HB1068 , HB1134 , HB1137 , HB1234 , HB1235 , HB1236 , HB961 , HB399 , HB868 , HB905 , HB180 , HB192 , HB284 , HB476 , HB915 , HB952 , HB1006 , HB401 , HB51 , HB58 , HB140 , HB982 , HB1010 , HB750 , HB911 , HB977 , HB901 , HR20 , HR74 , HB9 , HB151 , HB193 , HB310 , HB393 , HB459 , HB577 , HB582 , HB605 , HB614 , HB615 , HB682 , HB733 , HB773

Keywords: commendation, leadership, energy sector, Shell USA, Louisiana pride, House Resolution 134, HR134, honorary resolution, Bob Lupo, Robert E. Smith Lupo, Lakeview, New Orleans, civic service, philanthropy, real estate development, Hurricane Katrina recovery, community service, charitable giving, public recognition, Louisiana House of Representatives